Persistent Pleural Effusion Treatment Following Cardiothoracic Surgery by Platelet-Fibrin Glue

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 1, 2017

Primary Completion Date

May 1, 2023

Study Completion Date

May 1, 2024

Conditions
Pleural Effusion
Interventions
DRUG

Platelet-Rich Plasma and Fibrin Glue

"Allogenic platelet-rich plasma with fibrin glue (PRP-FG) was derived from blood obtained from a blood bank. Peripheral blood (400 ml) was collected from a donor with a matching ABO blood type, and rigorous viral safety tests were conducted. Concentrated PRP (10 ml) was obtained by subjecting the sample to centrifugation at 4000 g for 15 min to separate the plasma from the sedimented platelets.~Fibrinogen was extracted from the separated plasma using cryoprecipitation. After freezing at -70°C followed by thawing at 4°C, fibrinogen concentrate (20 ml) was prepared by centrifugation at 6500 × g for 5 min. The concentrated PRP was combined with fibrinogen (30 ml).~Thrombin was generated from the plasma isolated during the second centrifugation step. The ionic strength and pH were adjusted to precipitate prothrombin. The resulting precipitate was separated by centrifugation and dissolved in a calcium ion solution, resulting in a final volume of 5 ml of thrombin solution."

Trial Locations (1)

99191-91778

Mashhad University of Medical Sciences, Mashhad

All Listed Sponsors
lead

Daryoush Hamidi Alamdari, PhD

OTHER

NCT06449131 - Persistent Pleural Effusion Treatment Following Cardiothoracic Surgery by Platelet-Fibrin Glue | Biotech Hunter | Biotech Hunter